MTNB (Matinas BioPharma Holdings) EBITDA Margin %: 0.00% (As of Mar. 2026)

What is Matinas BioPharma Holdings EBITDA Margin %?

Matinas BioPharma Holdings MTNB -4.18% 30 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates MTNB with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Matinas BioPharma Holdings ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Matinas BioPharma Holdings's EBITDA for the three months ended in Mar. 2026 was $-1.86 Mil. Matinas BioPharma Holdings's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Matinas BioPharma Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Matinas BioPharma Holdings (AMEX:MTNB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Matinas BioPharma Holdings EBITDA Margin % Related Terms

Matinas BioPharma Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Matinas BioPharma Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Matinas BioPharma Holdings EBITDA Margin % Chart

Matinas BioPharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

-72,587.88

-743.16

-2,082.57

0.00

Matinas BioPharma Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

MTNB vs DRMA, MBIO, ADIL: EBITDA Margin % Comparison

For the Biotechnology subindustry, Matinas BioPharma Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Matinas BioPharma Holdings EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's EBITDA Margin % falls into.

Save Embed

30GF Score

Matinas BioPharma Holdings Inc MTNB

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Matinas BioPharma Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Matinas BioPharma Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-6.504	/	0
	=	%

Matinas BioPharma Holdings's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-1.862	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Matinas BioPharma Holdings (MTNB) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Matinas BioPharma Holdings and its competitors. According to the industry distribution chart, Matinas BioPharma Holdings ranks #999999 out of 945 companies in the Biotechnology industry.

Is Matinas BioPharma Holdings' EBITDA Margin % too high?

Matinas BioPharma Holdings' current EBITDA Margin % is 0.00%. Based on the distribution chart, Matinas BioPharma Holdings ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Matinas BioPharma Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Matinas BioPharma Holdings' EBITDA Margin % compare to DRMA and MBIO?

According to the Biotechnology industry distribution chart, Matinas BioPharma Holdings ranks #999999 out of 945 companies for EBITDA Margin %. This places Matinas BioPharma Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Matinas BioPharma Holdings and its competitors. Matinas BioPharma Holdings's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Matinas BioPharma Holdings stock overvalued right now?

Matinas BioPharma Holdings (MTNB) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Matinas BioPharma Holdings' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Matinas BioPharma Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies DRMA MBIO ADIL PULM CDT RVPH GLMD MLEC RNAZ ARTL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921

Website https://www.matinasbiopharma.com

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

30GF Score

Get the complete analysis for MTNB

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.62

Price

View MTNB Analysis

See EBITDA Margin % data for all stocks →